Topic: transcranial magnetic stimulation
BrainsWay’s so-called depression helmet—which focuses powerful electromagnetic waves to stimulate and help rewire the neurons firing deep within the brain—picked up its second clearance from the FDA last August, making it the first noninvasive device treatment for obsessive-compulsive disorder.
The FDA has cleared the first medical device for treating ADHD: an at-home nerve stimulation system designed for children ages 7 to 12.
An FDA panel voted against clearance for Neuronix's transcranial magnetic stimulation device, which targets the brain’s memory and learning centers.
Brainsway, developer of transcranial magnetic device treatments for depression and OCD, plans to raise $30 million through a Nasdaq IPO.
The FDA granted de novo clearance to Brainsway’s transcranial magnetic stimulation system, the first noninvasive device treatment for OCD.
Neuronetics has begun trading on the Nasdaq with a $93.5 million IPO pricing 5.5 million shares of common stock at $17 each, under the symbol STIM.